AvalehtGNLX • NASDAQ
add
Genelux Corp
Viimane sulgemishind
3,40 $
Tänane vahemik
3,26 $ - 3,49 $
Aasta vahemik
1,60 $ - 5,89 $
Turuväärtus
125,74 mln USD
Keskmine maht
153,03 tuh
P/E suhe
-
Dividendimäär
-
Põhibörs
NASDAQ
Uudised
Finantsandmed
Kasumiaruanne
Käive
Puhastulu
| (USD) | märts 2025info | Y/Y muutus |
|---|---|---|
Käive | — | — |
Põhitegevusega seonduv kulu | 7,82 mln | −3,78% |
Puhastulu | −7,49 mln | 4,56% |
Puhaskasumimarginaal | — | — |
Puhaskasum aktsia kohta | −0,21 | 27,59% |
EBITDA | −7,76 mln | 3,41% |
Tõhus maksumäär | — | — |
Bilansiaruanne
Kogu vara
Kõik kohustused
| (USD) | märts 2025info | Y/Y muutus |
|---|---|---|
Sularaha ja lühiajalised investeeringud | 35,10 mln | 78,85% |
Kogu vara | 38,98 mln | 57,99% |
Kõik kohustused | 9,14 mln | −4,72% |
Kogu omakapital | 29,85 mln | — |
Emiteeritud aktsiate arv | 37,30 mln | — |
Hinna ja väärtuse suhe P/B | 4,25 | — |
Varade tasuvus | −53,02% | — |
Kapitali tasuvus | −65,38% | — |
Rahavoog
Raha ja raha ekvivalentide muutus
| (USD) | märts 2025info | Y/Y muutus |
|---|---|---|
Puhastulu | −7,49 mln | 4,56% |
Põhitegevuse rahakäive | −5,44 mln | −24,83% |
Investeeringute raha | 3,51 mln | 307,51% |
Finantseerimise raha | 9,57 mln | 1 290,55% |
Raha ja raha ekvivalentide muutus | 7,64 mln | 242,64% |
Tasuta rahavoog | −2,66 mln | −103,16% |
Teave
Genelux Corporation is a publicly traded late clinical-stage company developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus with a large engineering capacity.
The core of Genelux’s discovery and development efforts revolves around the company's proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec.
The company is currently entered its pivot Phase 3 study in Platinum resistant/refractory ovarian cancer. Trial design based on VIRO-15 Phase 2 trial which showed independent anti-tumor activity of Olvi-Vec and reversal of platinum resistance in the TME. Wikipedia
Asutatud
2001
Veebisait
Töötajate arv
24
